Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS.

Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts say
Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS.